We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » 483 Roundup: FDA Raps Four Facilities for Quality Failures
483 Roundup: FDA Raps Four Facilities for Quality Failures
FDA inspections revealed good manufacturing practice and other deficiencies at drug manufacturing facilities in New Jersey, Vermont and California, leading to Form 483 inspection observations for four firms.